Aligning kidney function assessment in patients with cancer to global practices in internal medicine

作者：Geeta Sandhu, Josephine A. Adattini, Evangeline Armstrong Gordon, Niamh O’Neill, Corrine Bagnis, Pinkie Chambers, Jennifer Martin, A. Flynn, Karim Yaqub Ibrahim, Meg Jardine, David Wayne Johnson, Graham R.D. Jones, Christos Stelios Karapetis, Aisling Kelly, Ganessan Kichenadasse, David Simon Kliman, Winston Liauw, Catherine J. Lucas, Andrew John Mallett, Jolanta Małyszko, Michael Michael, Carol A. Pollock, Darren M. Roberts, Mitchell H. Rosner, David J. M. Routledge, Carla E. Scuderi, Julia Shingleton, Jake Shortt, Jim Siderov, Ben Sprangers, Brian N. Stein, David J. Tunnicliffe, Kate Webber, Robyn Lynne Ward · 发表于：EClinicalMedicine · 年份：2025 · DOI：10.1016/j.eclinm.2025.103102 · 被引用次数：7 · 研究领域：Chronic Kidney Disease and Diabetes、Renal cell carcinoma treatment、Acute Kidney Injury Research

The kidney disease: Improving Global Outcomes (KDIGO) guideline recommends assessing kidney function using glomerular filtration rate (GFR) either through direct measurement or through estimation (eGFR) and describes a standardised classification of reduced kidney function. KDIGO guidelines have been adopted by most internal medicine specialities for the assessment and classification of kidney function, but not by cancer medicine. The development of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) aims to overcome the perceived challenges with KDIGO recommendations by describing their utility in patients with cancer. Two virtual, consensus building workshops were held consecutively, involving international, multidisciplinary participants (Part 1 of ADDIKD development). During these workshops, three consensus recommendations were agreed upon based on KDIGO's principles; to standardise kidney function assessment, classify kidney function, and determine a uniform approach to dose anticancer drugs in patients with reduced kidney function. Cancer clinicians attending the workshops identified issues regarding the adoption of KDIGO's recommendations. These issues were addressed by nephrologists, clinical pharmacologists, and other clinicians with extensive experience in the contemporary assessment of kidney function. The key concern for cancer specialists was a hesitancy to move away from the familiar and long-standing practice of using ...